Premium
The role of mTOR in ovarian Neoplasms, polycystic ovary syndrome, and ovarian aging
Author(s) -
Liu Jin,
Wu DaiChao,
Qu LiHua,
Liao HongQing,
Li MeiXiang
Publication year - 2018
Publication title -
clinical anatomy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.667
H-Index - 71
eISSN - 1098-2353
pISSN - 0897-3806
DOI - 10.1002/ca.23211
Subject(s) - pi3k/akt/mtor pathway , rptor , polycystic ovary , protein kinase b , medicine , cancer research , signal transduction , ovary , kinase , microbiology and biotechnology , biology , insulin , insulin resistance
The mammalian target of rapamycin, mTOR, is a serine‐threonine protein kinase downstream of the phosphatidylinositol 3‐kinase (PI3K)‐AKT axis. The pathway can regulate cell growth, proliferation, and survival by activating ribosomal kinases. Recent studies have implicated the mTOR signaling pathway in ovarian neoplasms, polycystic ovary syndrome (PCOS) and premature ovarian failure (POF). Preclinical investigations have demonstrated that the PI3K/AKT/mTOR pathway is frequently activated in the control of various ovarian functions. mTOR allows cancer cells to escape the normal biochemical system and regulates the balance between apoptosis and survival. Some recent studies have suggested that involvement of the mTOR signaling system is an important pathophysiological basis of PCOS. Overexpression of the mTOR pathway can impair the interaction of cumulus cells, lead to insulin resistance, and affect the growth of follicles directly. The roles of mTOR signaling in follicular development have been extensively studied in recent years; abnormalities in this process lead to a series of pathologies such as POF and infertility. To improve understanding of the role of the mTOR signaling pathway in the pathogenesis and development of ovarian diseases, here we review the roles of mTOR signaling in such diseases and discuss the corresponding therapeutic strategies that target this pathway. Clin. Anat. 31:891–898, 2018. © 2018 Wiley Periodicals, Inc.